Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | June 03, 2026 | June 05, 2026 |
| Zymeworks Inc.ZYME · Entity 4458 | EVP, Chief Financial Officer | April 06, 2026 | April 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,934 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 22,934 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03 | Direct | 16,999 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Zymeworks Inc.
Report date April 06, 2026 · Filed April 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.84 · Expires 2036-04-05 | Direct | 178,000 |
Reported balance
After 2026-04-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-06 · Grant · Acquired 178,000 · Balance 178,000 F1: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 119,000 |
Reported balance
After 2026-04-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-06 · Grant · Acquired 119,000 · Balance 119,000 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3: RSUs vest in four equal annual installments beginning on first anniversary of grant date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2026-04-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-06 · Grant · Acquired 50,000 · Balance 50,000 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F4: RSUs vest in three equal annual installments beginning on first anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F3: RSUs vest in four equal annual installments beginning on first anniversary of grant date.
F4: RSUs vest in three equal annual installments beginning on first anniversary of grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:27 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 16,999 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001970438-26-000002 · primarydocument.xml · derivative · entry 2 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,999 Underlying: Ordinary Shares · 16,999 shares Expires 2036-06-03 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:27 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001970438-26-000002 · primarydocument.xml · nonDerivative · entry 1 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,934 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:53 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,945 | $15.77 | $46,444.71 |
DisclosureSEC source: 0001970438-26-000001 · primarydocument.xml · nonDerivative · entry 1 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,324 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 18:24 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-145305 · ownership.xml · derivative · entry 3 Stafford Kristin · CIK 0001970438 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F4 · derivative.exercise_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. F4 · derivative.expiration_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 18:24 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 119,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-145305 · ownership.xml · derivative · entry 2 Stafford Kristin · CIK 0001970438 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 119,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F3 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 18:24 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 178,000 | $0.00 Strike: $25.84 | $0.00 |
DisclosureSEC source: 0001193125-26-145305 · ownership.xml · derivative · entry 1 Stafford Kristin · CIK 0001970438 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,000 Underlying: Common Stock · 178,000 shares Expires 2036-04-05 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 16,697 | $0.00 Strike: $16.72 | $0.00 |
DisclosureSEC source: 0001562180-25-004561 · primarydocument.xml · derivative · entry 2 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,697 Underlying: Ordinary Shares · 16,697 shares Expires 2035-06-04 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004561 · primarydocument.xml · nonDerivative · entry 1 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,269 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 999 | $17.28 | $17,258.92 |
DisclosureSEC source: 0001562180-25-004441 · primarydocument.xml · nonDerivative · entry 1 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,054 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 21:43 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 6,229 | $0.00 Strike: $23.13 | $0.00 |
DisclosureSEC source: 0001562180-24-004765 · primarydocument.xml · derivative · entry 2 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,229 Underlying: Ordinary Shares · 6,229 shares Expires 2034-06-04 F2 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 21:43 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 4,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004765 · primarydocument.xml · nonDerivative · entry 1 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,053 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:34 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 15,873 | $0.00 Strike: $72.02 | $0.00 |
DisclosureSEC source: 0001562180-23-004074 · primarydocument.xml · derivative · entry 1 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,873 Underlying: Ordinary Shares · 15,873 shares Expires 2033-05-08 F1 · derivative.exercise_date: These stock options will vest in equal parts on the first, second and third anniversary of the grant date. Read SEC document |
| May 09, 2023 Filed May 17, 2023 20:58 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 15,873 | $0.00 Strike: $70.02 | $0.00 |
DisclosureSEC source: 0001562180-23-004210 · primarydocument.xml · derivative · entry 1 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,873 Underlying: Ordinary Shares · 15,873 shares Expires 2033-05-08 F1 · derivative.exercise_price: Incorrectly listed in the original filing. This is the correct amount. F2 · derivative.exercise_date: These stock options will vest in equal parts on the first, second and third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.